HLX 87
Alternative Names: GQ-1005; HLX-87Latest Information Update: 29 Aug 2025
At a glance
- Originator Suzhou GeneQuantum Healthcare
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III HER2 positive breast cancer
- Phase I Solid tumours
Most Recent Events
- 19 Aug 2025 HLX 87 licensed to Shanghai Henlius Biotech in China and certain overseas countries
- 28 Feb 2025 HLX 87 approved to initiate a phase III trial for HER2-positive non-surgical resection/metastatic breast cancer
- 28 Feb 2025 Suzhou GeneQuantum Healthcare plans to initiate a phase III trial for HER2-positive Breast cancer (Inoperable/Unresectable, Metastatic disease)